-
1.发明申请公开(公告)号：US20130064805A1
公开(公告)日：2013-03-14
申请号：US13667294
申请日：2012-11-02
发明人： Hitoshi Sakuraba , Youichi Tajima , Mai Ito , Seiichi Aikawa , Fumiko Aikawa
CPC分类号： C12N9/2465 , A61K38/00 , C12N9/2402 , C12Y302/01022 , C12Y302/01049
摘要： The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
摘要翻译： 本发明提供作为法布里病的酶替代疗法的酶，不具有过敏性副作用的具有α-半乳糖苷酶活性的蛋白质在血液中显示高稳定性，并且可以容易地加入到 受影响器官的细胞。 本发明的蛋白质是通过改变野生型人α-N-乙酰半乳糖胺酶活性位点的结构而获得α-半乳糖苷酶活性的蛋白质。
-
2.发明授权公开(公告)号：US07858313B2
公开(公告)日：2010-12-28
申请号：US11896256
申请日：2007-08-30
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： A method of evaluating drug sensitivity or disease vulnerability, includes linking a gene polymorphism in a GIRK channel gene or a haplotype comprising the gene polymorphism to individual drug sensitivity or individual disease vulnerability.
摘要翻译： 一种评估药物敏感性或疾病脆弱性的方法，包括将GIRK通道基因中的基因多态性或包含基因多态性的单体型与个体药物敏感性或个体疾病易感性相关联。
-
3.发明申请公开(公告)号：US20100240552A1
公开(公告)日：2010-09-23
申请号：US12597028
申请日：2008-04-25
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention provides a method for predicting the difference in drug sensitivity among individuals by using a genetic polymorphism of the POMC gene. Specifically, the present invention provides a method for evaluating drug sensitivity, comprising associating a genetic polymorphism of POMC gene with an individual drug sensitivity.
摘要翻译： 本发明提供一种通过使用POMC基因的遗传多态性预测个体间药物敏感性差异的方法。 具体而言，本发明提供药物敏感性评价方法，其特征在于，将POMC基因的遗传多态性与个体药物敏感性相关联。
-
4.发明申请Nucleic acid construct containing full length genome of human hepatitis C virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus particle 有权含有人丙型肝炎病毒全长基因组的核酸构建体，转移有核酸构建体的重组全长病毒基因组复制细胞及其生产丙型肝炎病毒颗粒的方法公开(公告)号：US20100047896A1
公开(公告)日：2010-02-25
申请号：US12583465
申请日：2009-08-21
申请人： Takaji Wakita , Takanobu Kato , Tomoko Date , Michiko Miyamoto , Jun-ichi Tanabe , Saburo Sone
发明人： Takaji Wakita , Takanobu Kato , Tomoko Date , Michiko Miyamoto , Jun-ichi Tanabe , Saburo Sone
CPC分类号： C12N7/00 , A61K2039/525 , C07K16/109 , C12N15/86 , C12N2770/24221 , C12N2770/24243 , C12N2840/203 , G01N33/5767
摘要： The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.
摘要翻译： 本发明提供了使用细胞培养系统有效复制含有全长HCV基因组序列的RNA的方法和含有全长HCV复制子RNA或全长HCV基因组RNA的HCV病毒颗粒的方法。 此外，本发明涉及一种生产丙型肝炎病毒颗粒的方法，其包括培养细胞，其中包含包含基因型2a的丙型肝炎病毒的全长基因组RNA序列的核苷酸序列的复制子RNA至少一个选择标记 基因和/或至少一个报告基因和至少一个IRES序列或基因型2a的丙型肝炎病毒的全长基因组RNA，并在培养基中产生病毒颗粒。 此外，本发明还涉及丙型肝炎疫苗和抗丙型肝炎病毒颗粒的抗体。
-
公开(公告)号：US20090298098A1
公开(公告)日：2009-12-03
申请号：US12480983
申请日：2009-06-09
申请人： Masao KAWAKITA , Kyoko HIRAMATSU , Keiichi TAKAHASHI , Naotaka HAMASAKI , Koji YAMAGUCHI , Tsunehisa KAKU , Koichiro MUTA , Munechika ENJOJI , Seiji NAITO , Jun HAYASHI , Shoshu MITSUYAMA , Hiroyuki YAMASHITA , Toru INOUE , Masato KATO
发明人： Masao KAWAKITA , Kyoko HIRAMATSU , Keiichi TAKAHASHI , Naotaka HAMASAKI , Koji YAMAGUCHI , Tsunehisa KAKU , Koichiro MUTA , Munechika ENJOJI , Seiji NAITO , Jun HAYASHI , Shoshu MITSUYAMA , Hiroyuki YAMASHITA , Toru INOUE , Masato KATO
IPC分类号： G01N33/574
CPC分类号： G01N33/574 , C07K16/30
摘要： A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.
摘要翻译： 包含二乙酰精胺的肿瘤标志物和评价肿瘤状态的方法，包括使抗体与二乙酰精胺与生物样品反应，从而检测二乙酰精胺，并使用获得的检测结果作为指标来评价肿瘤的状态。
-
公开(公告)号：US20090234102A1
公开(公告)日：2009-09-17
申请号：US12241868
申请日：2008-09-30
CPC分类号： C07K16/286 , C07K16/40 , C07K2317/73 , C07K2317/76
摘要： The present invention aims to provide hepatitis C virus inhibitors capable of inhibiting viral replication in hepatitis C virus-infected cells.The replication of hepatitis C virus can be inhibited and hepatitis C virus-infected cells can be specifically injured by specifically inhibiting BGT-1 or AKR1C1 involved in the replication of hepatitis C virus. Thus, viral inhibitors comprising a substance inhibiting BGT-1 or AKR1C1 are effective for the treatment of hepatitis C.
摘要翻译： 本发明旨在提供能够抑制丙型肝炎病毒感染细胞中病毒复制的丙型肝炎病毒抑制剂。 可以抑制丙型肝炎病毒的复制，通过特异性抑制丙型肝炎病毒复制中的BGT-1或AKR1C1可以特异性地损伤丙型肝炎病毒感染的细胞。 因此，包含抑制BGT-1或AKR1C1的物质的病毒抑制剂对于治疗丙型肝炎是有效的。
-
公开(公告)号：US07935336B2
公开(公告)日：2011-05-03
申请号：US12084982
申请日：2006-11-17
申请人： Hitoshi Sakuraba , Youichi Tajima , Mai Ito , Seiichi Aikawa , Fumiko Aikawa
发明人： Hitoshi Sakuraba , Youichi Tajima , Mai Ito , Seiichi Aikawa , Fumiko Aikawa
CPC分类号： C12N9/2465 , A61K38/00 , C12N9/2402 , C12Y302/01022 , C12Y302/01049
摘要： The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
摘要翻译： 本发明提供作为法布里病的酶替代疗法的酶，不具有过敏性副作用的具有α-半乳糖苷酶活性的蛋白质在血液中显示高稳定性，并且可以容易地加入到 受影响器官的细胞。 本发明的蛋白质是通过改变野生型人α-N-乙酰半乳糖胺酶活性位点的结构而获得α-半乳糖苷酶活性的蛋白质。
-
公开(公告)号：US07579166B2
公开(公告)日：2009-08-25
申请号：US10480790
申请日：2002-06-14
申请人： Yasunori Chiba , Yoshifumi Jigami , Hitoshi Sakuraba , Kazuo Kobayashi , Makoto Takeuchi , Yoriko Takeuchi, legal representative
CPC分类号： C12P21/005 , A61K36/064 , A61K38/17 , C12N9/1051 , A61K2300/00
摘要： A process for producing a lysosomal enzyme having a mannose-6-phosphate-containing acidic sugar chain, wherein the process comprising: culturing in a medium yeast cells obtained by introducing a lysosomal enzyme gene into a sugar chain biosynthetic enzyme gene mutant strain of yeast, collecting a lysosomal enzyme having a phosphate-containing sugar chain from the culture, and then treating the enzyme with α-mannosidase; and pharmaceutical compositions for treatment of human lysosomal enzyme deficiencies produced by the process. The genetic engineering technique using the yeast according to the present invention allows large-amount and high-purity production of a glycoprotein having a phosphate-containing acidic sugar chain which can serve as a labeling marker for transporting into lysosomes in cells of mammals such as human. The glycoprotein having a phosphate-containing acidic sugar chain according to the invention may be utilized as a drug effective in treatment of human lysosomal enzyme deficiencies, etc.
摘要翻译： 一种生产含有甘露糖-6-磷酸的酸性糖链的溶酶体酶的方法，其中所述方法包括：在通过将溶酶体酶基因导入酵母的糖链生物合成酶基因突变菌株获得的培养基中培养酵母， 从培养物中收集含有含磷酸盐糖链的溶酶体酶，然后用α-甘露糖苷酶处理酶; 以及用于治疗由该方法产生的人溶酶体酶缺陷的药物组合物。 使用根据本发明的酵母的基因工程技术允许大量和高纯度产生具有含磷酸盐的酸性糖链的糖蛋白，其可以用作在诸如人类的哺乳动物的细胞中输送到溶酶体的标记标记 。 具有根据本发明的含磷酸盐酸性糖链的糖蛋白可以用作治疗人溶酶体酶缺陷等的药物。
-
9.发明申请公开(公告)号：US20090092972A1
公开(公告)日：2009-04-09
申请号：US11896256
申请日：2007-08-30
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： A method of evaluating drug sensitivity or disease vulnerability, includes linking a gene polymorphism in a GIRK channel gene or a haplotype comprising the gene polymorphism to individual drug sensitivity or individual disease vulnerability.
摘要翻译： 一种评估药物敏感性或疾病脆弱性的方法，包括将GIRK通道基因中的基因多态性或包含基因多态性的单体型与个体药物敏感性或个体疾病易感性相关联。
-
公开(公告)号：US09134313B2
公开(公告)日：2015-09-15
申请号：US12480983
申请日：2009-06-09
申请人： Masao Kawakita , Kyoko Hiramatsu , Keiichi Takahashi , Naotaka Hamasaki , Koji Yamaguchi , Tsunehisa Kaku , Koichiro Muta , Munechika Enjoji , Seiji Naito , Jun Hayashi , Shoshu Mitsuyama , Hiroyuki Yamashita , Toru Inoue , Masato Kato
发明人： Masao Kawakita , Kyoko Hiramatsu , Keiichi Takahashi , Naotaka Hamasaki , Koji Yamaguchi , Tsunehisa Kaku , Koichiro Muta , Munechika Enjoji , Seiji Naito , Jun Hayashi , Shoshu Mitsuyama , Hiroyuki Yamashita , Toru Inoue , Masato Kato
IPC分类号： G01N33/574 , C07K16/30
CPC分类号： G01N33/574 , C07K16/30
摘要： A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.
摘要翻译： 包含二乙酰精胺的肿瘤标志物和评价肿瘤状态的方法，包括使抗体与二乙酰精胺与生物样品反应，从而检测二乙酰精胺，并使用所获得的检测结果作为指标来评价肿瘤的状态。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.035 秒)
